Illumina Inc. stock gains on S&P 500 inclusion and collaboration news

Illumina Inc. stock (ISIN US4523271090) is trading close to a 52-week high, with a recent price of 218.22 USD as of September 4, 2026, supported by strong second-quarter earnings and the announcement that the genomics company will join the S&P 500 index later in September 2026 according to market data and index provider statements.

Index inclusion lifts Illumina into the S&P 500

According to S&P Dow Jones Indices data reported by PPC Land, Illumina will move from the S&P MidCap 400 into the S&P 500, taking a vacated seat effective prior to the opening of trading on September 21, 2026.

Market commentary compiled by Investors Business Daily notes that Illumina shares rose in after-hours trading following the inclusion announcement, reflecting investor expectations that entry into the large-cap benchmark could support demand for Illumina Inc. stock through index-tracking fund flows.

Earnings and valuation context for Illumina Inc. stock

Recent earnings data compiled by MarketBeat show that in its latest reported quarter, Illumina delivered earnings per share of 1.31 USD, beating a consensus estimate of 1.23 USD by 0.08 USD, with revenue up 9.4% year on year to 1.16 billion USD.

The same overview attributes Illumina with a net margin of 18.36% and a return on equity of 29.84% for that quarter, underlining that the company is converting its genomics platform demand into robust profitability.

Illumina has set its guidance for fiscal year 2026 at earnings per share of 5.30 to 5.40 USD, and research analysts compiling estimates in the MarketBeat survey expect full-year EPS of around 5.36 USD, which provides the key backdrop for how the market values Illumina Inc. stock.

Price data from WallStreetZen show that Illumina closed at 218.22 USD per share on September 4, 2026, with an indicated market capitalization of 32.95 billion USD as of September 5, 2026.

WallStreetZen classifies Illumina Inc. stock under the health care sector and lists the NASDAQ ticker ILMN, with a next earnings date indication of October 29, 2026, which fits the typical quarterly reporting rhythm for the company.

A valuation-focused article on Yahoo Finance highlights that Illumina currently trades on a price-earnings multiple of about 40.0 times its trailing earnings, above the roughly 36.6 times average for the broader life sciences industry and around 33.4 times for selected peers.

That same analysis suggests a fair value multiple closer to 26.9 times based on Illumina’s growth profile and margins, implying that Illumina Inc. stock is priced at a premium relative to both peers and the fair value benchmark despite the index inclusion and earnings beat.

Strategic collaboration with Novacyt underpins growth narrative

A collaboration article on Simply Wall St reports that in September 2026 Novacyt S.A. entered into a five-year Master Collaboration Agreement with Illumina.

This agreement sets a framework for joint product development and commercial projects, to be defined in separate agreements, and reinforces Illumina’s strategy of expanding its ecosystem through partnerships with diagnostics companies that can build on its sequencing and genomics platforms.

Sector comparisons in the same commentary note that Illumina generates around 798 million USD in free cash flow on 4.5 billion USD of trailing revenue, with trailing EPS of 5.28 USD, figures that underpin the company’s ability to invest in collaborations while maintaining shareholder-focused financial metrics.

Illumina’s core products and genomics platform

Illumina’s business centers on next-generation sequencing systems and consumables used by research institutions, clinical laboratories and biopharmaceutical companies to analyze genetic variation and function.

Key product families include benchtop and high-throughput sequencing instruments, associated reagents and software, which together drive recurring revenue and support the free cash flow profile described in recent financial commentary.

Illumina Inc. stock price and market snapshot

Based on price data from WallStreetZen, Illumina Inc. stock traded at 218.22 USD per share as of September 4, 2026, with an indicated market capitalization of 32.95 billion USD as of September 5, 2026 and the NASDAQ listing under ticker ILMN.